TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes from baseline in laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Methamphetamine Doses Self-Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adenosine- and caffeine induced vasomotion (blood flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post-occlusive reactive hyperemic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency, Severity, and Duration of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events Leading to Death
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of Urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clearance of creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clearance of total protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clearance of albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clearance of Beta 2-microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Free light chains kappa of Immunoglobulins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GCF ALP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients terminating treatment due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of air removed from intravenous tubing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of air removed from intravenous tubing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Corticosteroid-Requiring cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of the COBIOPHAD device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of the COBIOPHAD device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in adherence to dietary recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in adherence to physical activity recommendations (Activity Tracker)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in adherence to physical activity recommendations (IPAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of referrals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total cholesterol (Total-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-density lipoprotein -cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low-density lipoprotein -cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Emotional Control Subscale of the BRIEF-Parent
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression Improvement for DESR
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Goniometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of visual phenomena
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional connectivity in the Default Mode Network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Mortality Ratio
Endpoint domain: Mortality/survival
Primary endpoint: 30% decrease in VAS score on mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of attrition based on number of patients who failed to complete the two-month study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total retention across the two month follow-up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction with the timing, content, and delivery of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Geometric mean titers (GMTs) to HPV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean seated diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Pressure Injury
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital stay after liver transplant
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Relative gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ZOSTAVAX-specific IFN-gamma Spot Forming Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Injection-site Adverse Experiences and Systemic Clinical Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Categorisation of SABA prescription
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Grade 2 or Higher Urogenital System Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Technical feasibility of alveolar compartments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Every day problem solving
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of alcoholic drinks consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times engaged in risky sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toronto Nocturnal Hypersalivation Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale - Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analogue Scale - Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Simpson-Angus Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Global Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: miRNAs expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: fatal or non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Time to first respiratory exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Continuous standardized uptake values (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on the visual-analogue scales (VAS) for back and legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of reirradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospital for special surgery knee score postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale postoperative
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Evaluation of cartilage repair under MRI postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean daytime/24 hour BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numbers reaching target BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Insulin Resistance measured by HOMA-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in glycated Haemoglobin measured: HBA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Cardiovascular Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Peritonitis Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of biologically active doses of CYT107
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Frequency of Point-of-care Ultrasound Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: UC remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cumulative radio frequency (RF) delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: improved neurological functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: acute postoperative pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Lenses With Axis Orientation ≤ 10 Degrees From Ideal Location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced expiratory volume and peak expiratory volume/second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum change from baseline in Panic Symptom Scale (PSS) sum intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Obstructive Sleep Apnea (OSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Apraglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of Apraglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GFR / ERPF changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: rates of clinical success (cure + improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal voluntary contraction (MVC) of quadriceps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in frequency of recurrent syncopal spells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Reported Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Asthma Control Test (ACT) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number and duration of high atrial frequency episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subject retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complicated evolution linked with port wine stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Contraceptive method choice and continuation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Accuracy of ultrasonography for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of racially/ethnically diverse participants enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of women that develop preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Post-traumatic Stress Disorder Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent Report of Behavioral Problems
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Teacher Report of Behavior Problems
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: gastric conduit failures
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to clinical guidelines for suspected Pulmonary Embolism
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Etiology of community-acquired sepsis and severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrence Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Ischemic stroke outcome
Endpoint domain: Mortality/survival
Primary endpoint: Physical complaints due to injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Device-oriented composite end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Prostate-Specific Antigen (PSA) at the Indicated Time Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in non-invasive tear film break up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Primary Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of ovarian endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Potential inappropriate medication (PIA)
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of Serum FGF19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epigenetic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-lead ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycosylated Haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of translated PLSs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Weight at a gestational age of 40 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants in Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Delivery within 2 weeks of the trauma event
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Objective Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oseltamivir Carboxylate AUC12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects in Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in sitting systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variability in bioavailability of LA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parental knowledge and attitudes related to vaccines
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parathyroid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent reduction in lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rate of Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Skin/nail sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Disease Progression to a New WHO Stage 4 Event or Death
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in CD4% 72 Weeks After ART Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppressed HIV RNA Viral Load 48 Weeks After Randomisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Sudden Infant Death Syndrome (SIDS)
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Loss of HBeAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time Taken to Achieve Adequate Akinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score for Local Anaesthetic Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score for Cataract Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Criticism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of motor Blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs) related to Eye Disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with an abnormal Lung Clearance Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum tolerated dose of Lapatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of binge drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: WOMAC self assessment of physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hemophilia Joint Health Scoring (HJHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BMI (body mass index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Pediatric's Quality of life Scale (PedsQL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lobene Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saxton & Ouderaa Bleeding Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quigley, Hein & Turesky Dental Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cervico-urethral hypermobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C3 serum measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum C3 breakdown products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: alternative pathway (AP) complement activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Heterogeneity of hypoxia as measured by EF5 binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heterogeneity of CA9 expression by immunohistochemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heterogeneity of glucose and lactate by bioluminescence imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: nocturnal pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes